Alimera Sciences, Inc.

NasdaqGM:ALIM Voorraadrapport

Marktkapitalisatie: US$301.3m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Alimera Sciences Beheer

Beheer criteriumcontroles 1/4

De CEO Alimera Sciences is Rick Eiswirth, benoemd in Jan2019, heeft een ambtstermijn van 5.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.26M, bestaande uit 18.5% salaris en 81.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.6% van de aandelen van het bedrijf, ter waarde $ 1.80M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.1 jaar en 2.3 jaar.

Belangrijke informatie

Rick Eiswirth

Algemeen directeur

US$3.3m

Totale compensatie

Percentage CEO-salaris18.49%
Dienstverband CEO5.7yrs
Eigendom CEO0.6%
Management gemiddelde ambtstermijn2.1yrs
Gemiddelde ambtstermijn bestuur2.3yrs

Recente managementupdates

Recent updates

Seeking Alpha • Sep 11

Alimera Sciences: Deal Closing After All, CVR Still Attractive

Summary Alimera Sciences, Inc. is being acquired by ANI Pharmaceuticals for $5.50 per share, with a contingent value right, or CVR, potentially adding up to $0.50 per share. Despite initial delays and Alimera suing ANI to close the deal, ANI remains committed, expecting to resolve closing conditions promptly. The deal is highly synergistic, adding durable assets to ANI's portfolio, with significant revenue growth and accretion expected by 2025. At $5.54 per share, Alimera Sciences stock is attractive, offering potential CVR payouts based on achievable sales targets, making it a compelling investment. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Alimera Sciences: Cheap CVR Optionality

Summary Alimera Sciences is being acquired by a larger peer at $5.5/share + CVR of up to 50 cents. In this article, I will focus on a CVR play with only a 10-cent outlay and a potential payout of up to 50 cents. The merger-related risks are minimal, and there are arguments that suggest the CVR milestones could be met. Read the full article on Seeking Alpha
Analyseartikel • Jun 18

Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

You may think that with a price-to-sales (or "P/S") ratio of 1.9x Alimera Sciences, Inc. ( NASDAQ:ALIM ) is a stock...
Analyseartikel • Feb 15

Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Alimera Sciences, Inc.'s ( NASDAQ:ALIM ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a buy right...
Analyseartikel • Dec 30

Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analyseartikel • Oct 13

Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

There wouldn't be many who think Alimera Sciences, Inc.'s ( NASDAQ:ALIM ) price-to-sales (or "P/S") ratio of 2.5x is...
Analyseartikel • Sep 13

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Oct 06

Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Alimera Sciences (NASDAQ:ALIM) said on Thursday a post-hoc analyses from a Phase 4 study showed that median treatment frequency in diabetic macular edema patients treated with its therapy Iluvien 0.19 mg was lower than from patients on other regimens. Iluvien provides diabetic macular edema patients with continuous therapy for up to 36 months. The treatment significantly reduced the number of eyes requiring anti-VEGF, corticosteroid, and laser therapy and reduced the total number of therapies administered by 46%. Iluvien is a intravitreal implant in the United States for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
Seeking Alpha • Sep 20

Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Alimera Sciences (NASDAQ:ALIM) on Tuesday said it had been granted reimbursement for its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in Ireland. ALIM said the reimbursement was granted to the its Ireland-based European unit by the Health Service Executive Corporate Pharmaceutical Unit and National Centre for Pharmacoeconomics in Ireland. The reimbursement decision by Ireland adds to a string of such grants earlier this year by Portugal, France and Italy. "We continue to expand the availability of our non-infectious uveitis indication in our International Segment with it now accessible to patients in all of our direct markets in addition to our key distributor markets," ALIM CEO Rick Eiswirth said in a statement. ALIM stock closed -3.6% at $5.38 on Monday.
Seeking Alpha • Aug 09

Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Alimera Sciences (NASDAQ:ALIM) on Tuesday said it had been granted reimbursement for its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in Portugal. ALIM said the reimbursement was granted by Portugal's National Authority of Medicines and Health Products with no change to the current label. The reimbursement decision by Portugal follows similar approvals for Iluvien in France and Italy in July. “This summer has been a productive one for expanding availability of our non-infectious uveitis indication in our International Segment with it soon to be accessible to patients in all of our direct markets in addition to our key distributor markets,” ALIM CEO Rick Eiswirth said in a statement. ALIM said it is planning to launch Iluvien in Portugal and France in Q3. Alimera (ALIM) stock closed +2.6% at $7.18 on Monday.
Seeking Alpha • Jul 22

Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Alimera Sciences (NASDAQ:ALIM) on Friday said it would launch its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in France through its distribution partner Horus Pharma. ALIM said Horus had been granted pricing and reimbursement approval for Iluvien for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye from the Economics Committee for Health Products. Alimera (ALIM) did not disclose the pricing determination for Iluvien. Earlier in July, ALIM got Italian regulatory approval and was granted pricing and reimbursement for Iluvien for the same indication. ALIM stock closed +0.8% at $5.33 on Thursday.
Seeking Alpha • Jul 08

Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Alimera Sciences (NASDAQ:ALIM) has got Italian regulatory approval for its Iluvien injection for the treatment of uveitis, a form of eye inflammation. ALIM's Ireland-based European unit, Alimera Sciences Europe, got an approval and was granted pricing and reimbursement for Iluvien by the Italian Medicines Agency (AIFA), Alimera said in a statement on Friday. The indication was for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. ALIM said it would launch Iluvien through its Italian distribution partner, ophthalmic company SIFI. It did not disclose the pricing determination for Iluvien. ALIM stock closed marginally higher at $5.32 on Thursday.
Analyseartikel • Mar 24

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analyseartikel • Nov 06

Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Alimera Sciences, Inc...
Analyseartikel • Aug 24

Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Even though Alimera Sciences, Inc. ( NASDAQ:ALIM ) posted strong earnings recently, the stock hasn't reacted in a large...
Analyseartikel • Feb 11

Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Alimera Sciences, Inc. ( NASDAQ:ALIM ) shareholders will doubtless be very grateful to see the share price up 97% in...

Analyse CEO-vergoeding

Hoe is Rick Eiswirth's beloning veranderd ten opzichte van Alimera Sciences's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$15m

Mar 31 2024n/an/a

-US$23m

Dec 31 2023US$3mUS$603k

-US$21m

Sep 30 2023n/an/a

-US$21m

Jun 30 2023n/an/a

-US$25m

Mar 31 2023n/an/a

-US$17m

Dec 31 2022US$974kUS$580k

-US$18m

Sep 30 2022n/an/a

-US$18m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$7m

Dec 31 2021US$890kUS$550k

-US$4m

Sep 30 2021n/an/a

-US$1m

Jun 30 2021n/an/a

US$2m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$888kUS$550k

-US$5m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020n/an/a

-US$9m

Dec 31 2019US$977kUS$525k

-US$10m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

US$19m

Mar 31 2019n/an/a

US$22m

Dec 31 2018US$831kUS$495k

US$17m

Sep 30 2018n/an/a

US$11m

Jun 30 2018n/an/a

-US$22m

Mar 31 2018n/an/a

-US$23m

Dec 31 2017US$811kUS$425k

-US$22m

Compensatie versus markt: De totale vergoeding ($USD 3.26M ) Rick } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.59M ).

Compensatie versus inkomsten: De vergoeding van Rick is gestegen terwijl het bedrijf verliesgevend is.

CEO

Rick Eiswirth (56 yo)

5.7yrs
Tenure
US$3,261,480
Compensatie

Mr. Richard S. Eiswirth, Jr., also known as Rick, served as Interim Chief Financial Officer at Alimera Sciences, Inc. since 2022. He has been President of Alimera Sciences, Inc. since January 1, 2016 until...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Richard Eiswirth
CEO & Director5.7yrsUS$3.26m0.60%
$ 1.8m
Jason Werner
Chief Operating Officerless than a yearUS$1.39m0.0017%
$ 5.1k
Philip Ashman
President of International Operationsless than a yearUS$1.02m0.22%
$ 655.2k
David Holland
Co-Founder21.3yrsUS$541.72k0.35%
$ 1.0m
Elliot Maltz
CFO & Treasurerless than a yeargeen gegevens0%
$ 0
Christopher Visick
VP, General Counsel & Secretary5.8yrsgeen gegevensgeen gegevens
David Dyer
Chief Retina Specialist3.3yrsgeen gegevens0.0083%
$ 25.1k
Todd Wood
President of U.S. Operationsless than a yeargeen gegevens0%
$ 0
2.1yrs
Gemiddelde duur
55.5yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van ALIM wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Richard Eiswirth
CEO & Director5.7yrsUS$3.26m0.60%
$ 1.8m
Peter Pizzo
Independent Director14.4yrsUS$186.31k0.00092%
$ 2.8k
Margaret Pax
Directorless than a yearUS$96.42k0%
$ 0
Ross DeMont
Director1.7yrsUS$124.63k0%
$ 0
John Snisarenko
Independent Director5.2yrsUS$172.21k0.018%
$ 55.4k
Michael Kaseta
Independent Director1.5yrsUS$151.70k0%
$ 0
Adam Morgan
Chairman of the Board1.5yrsUS$165.75k0%
$ 0
Erin Parsons
Director2.8yrsUS$172.52k0%
$ 0
2.3yrs
Gemiddelde duur
53.5yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ALIM wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.3 jaar), wat duidt op een nieuw bestuur.

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2024/09/18 16:13
Aandelenkoers aan het einde van de dag2024/09/13 00:00
Inkomsten2024/06/30
Jaarlijkse inkomsten2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Alimera Sciences, Inc. wordt gevolgd door 12 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
James MolloyAlliance Global Partners
Andrew D'SilvaB. Riley Securities, Inc.
Caroline CornerCantor Fitzgerald & Co.